

Richat Abbas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12040306/publications.pdf>

Version: 2024-02-01

24
papers

2,098
citations

394421

19
h-index

610901

24
g-index

24
all docs

24
docs citations

24
times ranked

2441
citing authors

#	ARTICLE	IF	CITATIONS
1	A Thorough QT Study to Evaluate the Effects of a Supratherapeutic Dose of Sertraline on Cardiac Repolarization in Healthy Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 307-320.	1.6	7
2	Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions. <i>Drug Metabolism and Disposition</i> , 2017, 45, 390-398.	3.3	31
3	Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1191-1204.	3.5	56
4	Considerations in the early development of biosimilar products. <i>Drug Discovery Today</i> , 2015, 20, 1-9.	6.4	20
5	Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. <i>Drug Metabolism and Personalized Therapy</i> , 2015, 30, 57-63.	0.6	24
6	Population Pharmacokinetic and Pharmacodynamic Analysis of Bosutinib. <i>Drug Metabolism and Pharmacokinetics</i> , 2014, 29, 441-448.	2.2	21
7	Phase I Study of Neratinib in Combination With Temezirolimus in Patients With Human Epidermal Growth Factor Receptor 2-Dependent and Other Solid Tumors. <i>Journal of Clinical Oncology</i> , 2014, 32, 68-75.	1.6	179
8	Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 123-132.	2.3	32
9	A Clinical Study to Examine the Potential Effect of Lansoprazole on the Pharmacokinetics of Bosutinib when Administered Concomitantly to Healthy Subjects. <i>Clinical Drug Investigation</i> , 2013, 33, 589-595.	2.2	30
10	Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 1092-1100.	7.0	78
11	Ascending Single-Dose Study of the Safety Profile, Tolerability, and Pharmacokinetics of Bosutinib Coadministered With Ketoconazole to Healthy Adult Subjects. <i>Clinical Therapeutics</i> , 2012, 34, 2011-2019.e1.	2.5	18
12	A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects. <i>International Journal of Cancer</i> , 2012, 131, E304-11.	5.1	22
13	A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 191-199.	2.3	18
14	A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 221-227.	2.3	75
15	Effect of Ketoconazole on the Pharmacokinetics of Oral Bosutinib in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 1721-1727.	2.0	47
16	Pharmacokinetics of oral neratinib during coadministration of ketoconazole in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 522-527.	2.4	47
17	Safety and efficacy of bosutinib (SKI-606) in chronic Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. <i>Blood</i> , 2011, 118, 4567-4576.	1.4	406
18	A Single-Dose, Crossover, Placebo- and Moxifloxacin-Controlled Study to Assess the Effects of Neratinib (HKI-272) on Cardiac Repolarization in Healthy Adult Subjects. <i>Clinical Cancer Research</i> , 2010, 16, 4016-4023.	7.0	24

#	ARTICLE	IF	CITATIONS
19	Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1301-1307.	1.6	466
20	A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 2552-2558.	7.0	269
21	A Human Physiologically Based Pharmacokinetic Model for Trichloroethylene and Its Metabolites, Trichloroacetic Acid and Free Trichloroethanol. <i>Toxicology and Applied Pharmacology</i> , 1998, 152, 339-359.	2.8	101
22	A Physiologically Based Pharmacokinetic and Pharmacodynamic Model for Paraoxon in Rainbow Trout. <i>Toxicology and Applied Pharmacology</i> , 1997, 145, 192-201.	2.8	54
23	A Physiologically Based Pharmacokinetic Model for Trichloroethylene and Its Metabolites, Chloral Hydrate, Trichloroacetate, Dichloroacetate, Trichloroethanol, and Trichloroethanol Glucuronide in B6C3F1 Mice. <i>Toxicology and Applied Pharmacology</i> , 1997, 147, 15-30.	2.8	64
24	Gas Chromatographic Determination of Parathion and Paraoxon in Fish Plasma and Tissues. <i>Journal of Analytical Toxicology</i> , 1996, 20, 151-154.	2.8	9